JGC
TRVI icon

J. Goldman & Co’s Trevi Therapeutics TRVI Stock Holding History

J. Goldman & Co’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-900
Closed -$3.71K – 643
2024
Q4 		$3.71K Hold
900
– – ﹤0.01% 436
2024
Q3 		$3.01K Buy
+900
New +$2.67K ﹤0.01% 440

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

J. Goldman & Co's TRVI Position: Q2 2026 in Review

J. Goldman & Co reduced its Trevi Therapeutics (TRVI) stake by 66% in Q2 2026, selling an estimated $2.27M and leaving 80,998 shares worth $1.51M. The position accounts for 0.04% of the portfolio, ranked #394.

J. Goldman & Co first reported a position in TRVI in Q2 2022 and has held it in 17 quarters since. The position peaked at $7.25M in Q3 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • J. Goldman & Co held 80,998 shares of Trevi Therapeutics worth $1.51M as of Q2 2026.
  • J. Goldman & Co sold 155,961 Trevi Therapeutics shares in Q2 2026, an estimated $2.27M.
  • Trevi Therapeutics made up 0.04% of J. Goldman & Co's portfolio in Q2 2026, its #394 holding.
  • J. Goldman & Co first reported a position in Trevi Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • J. Goldman & Co's Trevi Therapeutics position peaked at $7.25M in Q3 2025.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.